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Nowisatimeofunprecedentedopportunityandprogressin
cancer drug development. Fueled by an explosion of infor-
mation about the biological underpinnings of cancer, new
drugs, directed at critical molecular targets, are being intro-
duced into cancer treatment at a rapid rate. Witness the
transformation of treatment for advanced kidney cancer, a
disease for which five new drugs have received FDA ap-
provalinjustthelast5years.Duringthissameinterval,tar-
geted therapies have been introduced for treatment of other
tumors that have historically been resistant to treatment
withcytotoxicchemotherapysuchashepatocellularcancer,
gastrointestinal stromal tumors, and glioblastoma. For
many other cancers, however, the promise of effective tar-
geted therapies remains unfulfilled. Cancer drug develop-
ment remains an expensive, inefficient, and risky business
with limited participation by oncologists and cancer pa-
tients in clinical trials. This has contributed to a limited im-
pact on mortality for many cancers and for millions
prolongs the daily challenges encountered with diagnosis
and treatment of their disease.
More than 800 drugs are now in clinical development
for cancer indications yet success rates in bringing drugs to
market remain in the range of only 5%–8%. Many factors
may contribute to these low success rates: little scientific
insight into the determinants of drug sensitivity and resis-
tance; poorly conceived and executed clinical development
plans; heterogeneous patient populations and lack of bio-
markerstoidentifypatientsmostlikelytobenefitfromspe-
cific treatments; unclear, conflicting, or burdensome
regulatory requirements; and lack of agreement among cli-
nicians, investigators, and regulators as to what constitutes
clinical benefit in some circumstances. Moreover, the same
biological insights that have enabled development of targeted
treatments now challenge product developers to focus on mo-
lecularly defined tumor subtypes, to develop analytically and
clinicallyvalidatedbiomarkerteststoguidetherapy,andtoin-
troduceclinicaltrialendpoints,otherthansurvival,thatobjec-
tively demonstrate meaningful clinical benefit. With the
introduction of molecular pathology, patients and their on-
cologistsnowdealwithagreatervarietyofmalignantdiseases
than ever before, each of which is less common than cancers
diagnosed by histology alone, and each of which likely bene-
fits from a unique approach to treatment. Finally, with many
new drugs slowing tumor progression rather than causing tu-
mor shrinkage, cancer drug trials may require more patients
andthemorefrequentuseofplacebocontrols,thuspresenting
greater recruitment challenges. Contemporary trials may re-
quire a long period of time to reach major clinical endpoints,
Correspondence: Richard L. Schilsky, M.D., Section of Hematology-Oncology, University of Chicago, 5841 South Maryland Avenue,
MC 2115, Chicago, Illinois 60637, USA. Telephone: 773-834-3914; Fax: 773-834-3915; e-mail: rschilsk@medicine.bsd.uchicago.
edu Received March 7, 2010; accepted for publication March 25, 2010; available online without subscription through the open access
option. ©AlphaMed Press 1083-7159/2010/$30.00/0 doi: 10.1634/theoncologist.2010-0079
The Oncologist
®
Cancer Treatment Reports
The Oncologist 2010;15:484–487 www.TheOncologist.commore expensive clinical documentation to record progression
events, and additional regulatory scrutiny, especially when
studies seek approval of both drugs and diagnostic tests that
are used to select patients for treatment.
In an effort to address some of these issues, the Engel-
berg Center for Health Care Reform at Brookings Institu-
tion and Friends of Cancer Research convened conferences
in 2008 and 2009, with support from the American Society
ofClinicalOncology,theAmericanAssociationforCancer
Research, the Lance Armstrong Foundation, and Susan G.
Komen for the Cure. The conferences aimed to frame key
issues and develop new approaches that would improve the
efficiency and reduce the cost of cancer drug development
whileensuringthatscientificrigorandregulatorystandards
arepreserved.Theconferenceformatfacilitatesmultisector
collaboration on specific issues in clinical research by con-
vening expert panels comprised of representatives from
academia, government, industry, and the patient commu-
nity that work during the months leading up to the confer-
encetoidentifyareasofconsensusandtoproposesolutions
to specific challenges in oncology drug development. Past
topics have included the following: issues relating to opti-
mized data collection for supplemental new drug applica-
tions; the utility and validity of blinded independent review
of progression events in clinical trials; the regulatory ap-
proach to drug and biomarker co-development; and the sci-
entific, clinical, and regulatory challenges of combining
targeted new molecular entities that may have limited anti-
tumoractivityassingleagents.Eachoftheseareaspresents
unique challenges and requires thoughtful solutions that re-
main focused on the overall goal to deliver safe and effec-
tive new therapies to cancer patients as quickly as possible.
Although the FDA has issued guidance on data collec-
tionrequirementsfornewdrugapplications,uncertaintyre-
mains regarding the type and extent of data collection
required. Sponsors therefore continue to collect compre-
hensive information on adverse events and use of concom-
itant medications for essentially all registration-directed
trials, even those seeking supplemental indications. Doing
so drives up cost, adds complexity, and more importantly,
may distract investigators from focusing on medically im-
portant new safety information and diminish their enthusi-
asm for participation in clinical trials that collect large
amountsofdatathatareneverusedtoinformregulatoryde-
cisions or change labeling. Many medically important new
drugs have initial and multiple supplemental indications.
The extent and nature of data collection for the supplemen-
talstudiesshouldbeguidedbywhatisalreadyknownabout
the safety profile and pharmacology of the drug, the simi-
larity of the intended new patient population to that for the
approved use, the potential for previously unrecognized
druginteractions,andtherisk/benefitassessmentforthein-
tended new use. At the same time, there are risks to reduc-
ing data collection requirements for supplemental
applications, particularly the possibility of missing new
safety signals. The expert panel tackling these issues pro-
posed adhering to certain core principles to mitigate these
risks, such as reducing data collection only if the existing
drug safety database was sufficient to support full regula-
tory approval of the initial indication, collecting serious ad-
verse events, deaths, and adverse events requiring dose
modification or discontinuation in all patients, and if med-
ically appropriate, collecting targeted adverse events in all
patientsthatarebasedontheknownsafetyprofileandphar-
macology of the drug. To address the question of “What
might be missed?” by otherwise reducing data collection, a
simulationexerciseledbytheAmericanSocietyofClinical
Oncology was undertaken to re-analyze data already col-
lected from eight completed randomized trials in both the
metastaticandadjuvantsettings.Thisanalysissuggeststhat
fewclinicallyimportanteventswouldbelikelytobemissed
and that as long as the core principles are followed, com-
prehensiveadverseeventdatacollectioncouldbelimitedto
only a subset of patients enrolled in trials that seek supple-
mental new indications.
Progression-free survival (PFS) is an endpoint being
used with greater frequency in pivotal randomized trials of
targeted therapies. PFS includes all patients in the study
analysis and has the advantage compared with overall sur-
vival of being reached sooner and of not being confounded
bytheimpactofsubsequentlinesoftherapy.However,PFS
is fraught with problems of defining what constitutes pro-
gression and when progression occurs and of minimizing
bias in assessment of progression events by the treating
physician, particularly in open label studies. To deal with
these issues, special care must be taken in the design of
studies that use PFS as a primary endpoint including
blinded treatment assignment whenever feasible, compre-
hensive assessment of all lesions at baseline, prospective
designation of target lesions in each patient, clear specifi-
cation of the frequency and modality of imaging assess-
ments, and others. PFS is, in many ways, the most complex
and expensive clinical endpoint used in oncology drug tri-
als. There is, of course, also the issue of the magnitude of
improvement in PFS that constitutes benefit to a patient if
there is no improvement in overall survival or symptom
control. Given the complexity of the PFS endpoint, FDA
has frequently required blinded independent assessment
and central review of progression events in registration-
directed trials. Such reviews add considerable time and ex-
pense to the conduct of clinical trials and legitimate
questions have been raised as to their ultimate utility in de-
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this issue carefully considered not only the utility of these
reviews but also the evidence that blinded independent re-
view can introduce other biases into evaluation of the study
results that may create new problems. On the basis of their
analysis, the panel concluded that a strategy of indepen-
dentlyreviewingapproximately20%ofthetotalstudypop-
ulationwouldgenerallybesufficienttodetectastatistically
significant hazard ratio 88% of the time in a study with a
largetreatmenteffect[1].Alargerauditmayberequiredfor
studies with a moderate treatment effect, but for studies
with a small treatment effect, the blinded review may itself
introduce sufficient random variation as to no longer be
useful to validate the investigator assessment.
Biomarker-driven clinical trials introduce regulatory
challenges when the goal is biomarker assay and drug co-
development in that the test and the drug must meet both
regulatory standards for marketing approval and clinical
use. Within the FDA, reviewers of in vitro diagnostic tests
and drugs reside in different centers of the agency (i.e.,
Center for Devices and Radiological Health and Center for
Drug Evaluation and Research) that apply separate review
processes to satisfy their respective statutes and regula-
tions. The requirement that both the drug and the test dem-
onstrate clinical benefit and the different evidentiary
standards applied by the two FDA oversight divisions cre-
ates many challenges. For example, although it may be suf-
ficient to demonstrate that a drug has clinical benefit in a
biomarker-defined population to obtain drug approval, reg-
ulatory approval of the biomarker test may also require
demonstration that the drug is ineffective in the biomarker-
negative patient population. Thus, investigators and spon-
sors may find it challenging to design clinical trials that are
acceptable to both divisions and provide conclusive evi-
denceofthesafetyandeffectivenessofboththetestandthe
drug.Analyticalvalidationofthetestisanecessitybutclin-
icalvalidationisincreasinglyrequiredbyFDAandmayre-
quire large prospective trials to generate data sets that
supportsuchclaims.Theexpertpaneltacklingthisissueset
out as a goal to develop a regulatory pathway that would
facilitate the accelerated development and approval of a
cancer therapy used in a population defined by a specific
biomarker test. The proposed criteria for this “targeted ap-
proval”arethatthedrugmustbeindicatedforuseincancer
treatment, the assay must be analytically validated, and the
drug must demonstrate, in a population defined by the test,
a prespecified statistically significant change in a clinical
endpoint that is reasonably likely to predict clinical benefit.
Under such circumstances, it is proposed that the FDA
would approve the drug for use in the population identified
by the biomarker test and approve the test for use in identi-
fyingthepatientpopulationfortreatmentwiththedrugwith
thecaveatthatthetesthasnotbeenprovenusefultoidentify
patients with expected lack of benefit from the drug. Post-
marketing studies would be required and would establish
the utility of the test and the drug in the biomarker-negative
population. It is tempting to speculate that such a strategy
couldbepursuedintheregulatoryreviewofdrugsthathave
recently shown high response rates in molecularly defined
patient populations such as patients with melanoma that
harbors a BRAF V600E mutation [2]. The panel proposed
that, in these circumstances, reimbursement by insurers for
off-label use of the drug would not occur until completion
of the postmarketing studies. This novel regulatory path-
waybuildsontheacceleratedapprovalpathwayfordrugsin
place at the FDA for nearly 2 decades and offers an ap-
proach to more efficient and less costly drug-biomarker co-
development.
Despite the many important advances in understanding
tumor biology and using biomarkers to identify and select
patients likely to benefit from or be resistant to treatment,
there are too few examples of clinically useful biomarkers
that can identify drug sensitivity and predict clinical bene-
fit. Why is it so difficult to identify positive predictive bio-
markers? The challenge lies primarily in understanding the
heterogeneity of cancer and the plasticity of the cancer ge-
nome. Tumors with drug-sensitizing mutations can simul-
taneously harbor or develop drug-resistance mutations, as
in the case of the EGFR T790M mutation [3]; there may be
downstream pathway activating mutations as in the case of
KRAS [4]; activation of a parallel pathway that circum-
vents a pharmacological block is also known to occur as in
the case of mesenchymal-epithelial transition factor gene
(MET) amplification causing resistance to small-molecule
EGFR inhibitors [5]; or pathway blockade can result in
feedback upregulation of the pathway to overcome the
block [6]. Overcoming the multiple redundancies and
crosstalkofcriticalsignalingpathwayswillrequirethattar-
geted therapies be used in combination to achieve optimal
effect.Suchcombinationsmightincludedrugsthathavelit-
tle or no activity as a single agent but that produce substan-
tial antitumor effects when used in biologically rational
combinations. Existing regulations require that, for fixed
combination drug products, the sponsor demonstrate the
contribution of each drug in the combination to the benefi-
cial effect of the combination product. Even when individ-
ual drugs are combined in a novel regimen, the FDA has
generally recommended that factorial trials be employed to
demonstrate the effects of the drugs individually as well as
together. But in the era of targeted therapy for cancer, such
an approach might be scientifically illogical, medically un-
feasible,andethicallyinappropriate.Theexpertpaneldeal-
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specific criteria for the development and regulatory ap-
proval of two new molecular entities given in combination,
particularly when one or both agents have little antitumor
activity as single agents. Such an approach must be driven
by a strong biological rationale and some preclinical evi-
denceofgreaterthanadditiveantitumoractivityforthepro-
posed combination. The toxicity profile of each individual
agentmustbecarefullystudiedanddocumentedandpoten-
tial pharmacological interactions between the agents must
be understood. With this information in hand, a clinical de-
velopment plan can be developed that efficiently evaluates
the combination against a standard of care to prove its clin-
ical utility. Modification of existing regulatory guidance to
enable such approaches will be critical to enable and incen-
tivize the rapid development of new targeted drug combi-
nations that will likely be essential to make more rapid
progress against cancer.
The thoughtful and creative approaches to solving vex-
ingproblemsincontemporarycancerdrugdevelopmentde-
scribed in this issue of The Oncologist are the result of an
inclusive, collaborative effort between clinical investiga-
tors,statisticians,regulatoryscientists,laboratoryresearch-
ers, patients, and drug and device manufacturers who were
convened around a common goal: to translate insights in
cancer biology into clinically useful, safer, and more effec-
tive products for patients and into policies that accelerate
their availability. The output of these expert panels illus-
trates the power of this collaboration to improve the sci-
entific, clinical, and regulatory approaches to drug de-
velopment and—hopefully—to accelerate the development
of safe and effective treatments for patients with cancer.
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